Materialise(US:MTLS) Yahoo Finance·2025-10-28 21:19Core Insights - The company reported a mixed performance in Q3 2025, with overall revenue under pressure but strong growth in the medical unit, particularly in the cardiac segment, driven by the acquisition of FEops and advancements in AI-driven simulation technology [5][6][17]. Business Highlights - The medical unit achieved double-digit growth, with a record revenue of EUR 33.3 million, up more than 10% compared to Q3 2024 [18][22]. - The cardiac segment saw significant advancements, including the release of a new version of FEops' heart guide and additional clinical evidence supporting the benefits of cardiac planners [6][7]. - The software segment experienced a 7% revenue decline to EUR 10.3 million, attributed to macroeconomic headwinds and unfavorable foreign exchange impacts, although 83% of the revenue was recurring [19][24]. - The manufacturing segment faced challenges, with a 17% revenue decline to EUR 22.7 million, but showed slight improvement compared to Q2 2025 [25][26]. Financial Performance - Consolidated revenue for Q3 2025 was EUR 66.3 million, a 3.5% decrease from the previous year, with a gross profit margin of 56.8% [17][27]. - Adjusted EBIT for the quarter was EUR 2.9 million, with an adjusted EBIT margin of 4.4% [17][20]. - The company generated a net profit of EUR 1.8 million, increasing its net cash position to EUR 67.7 million, driven by strong free cash flow [18][30]. Future Outlook - The company maintained its full-year guidance for 2025, expecting revenues between EUR 265 million and EUR 280 million and adjusted EBIT between EUR 6 million and EUR 10 million [33]. - The management expressed confidence in the company's resilience and ability to capture growth opportunities once market conditions improve [33].